Phaseline

Targets › IL25

IL25 (Interleukin-25): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jun 2028.

Cytokine produced by various cells such as eosinophils, T-helper type 2 (Th2) cells or epithelial cells that plays a role in internal safety of adaptive immune responses by regulating cytokine production. Promotes and augments T-helper type 2 responses locally or systemically. (UniProt, Q9H293)

Open in Phaseline: the race on IL25, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bionyra PharmaBYN-001
humanized IgG1 monoclonal antibody targeting IL-25
IL25Phase 1Atopic DermatitisJun 2028

Conditions

Atopic Dermatitis (1)

Modalities

protein or peptide (1)

Companies

Bionyra Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.